| abstract |
The present invention relates to a compound of formula (I) and salts thereof for use in human and veterinary medicine and solvates of any of these. In the formula I, the dotted line represents a bond; A is carbon or methylmethylidine; B is methylene, oxygen or bond; R1 and R2 are independently hydrogen, optionally substituted with alkoxy or phenyl, or alkenyl, or R1 and R2 together with the carbon atom to which they are attached form optionally a heteroatom selected from the group consisting of oxygen, sulfinyl, sulfonyl, and -NR6; in the case of benzene ring condensed; R3 is hydrogen or halo, R7 or -OR7; . R4 is hydrogen, alkyl, alkoxy, trifluoromethyl or halogen; R6 is hydrogen or alkyl; R7 is a monocyclic or bicyclic ring system, namely phenyl, thienyl, furyl, pyridinyl, pyrimidinyl, naphthyl, indanyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, indolyl, quinolinyl, isoquinolinyl, benzodioxolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl or benzodioxanyl, each of which ring systems is optionally substituted with one or two substituents, namely alkyl or alkoxy, optionally substituted with alkoxy or hydroxy, or thio, trifluoromethyl, or trifluoromethyl; m is 1 or 2; and n is 0, 1 or 2; with the proviso that when A is carbon, B is other than oxygen, or a salt thereof for human or veterinary use, or a solvate of any of these for use in human or veterinary medicine. The present invention also relates to the preparation of the above compounds, intermediates for the preparation thereof, and human and veterinary medicinal products containing MMP inhibitors containing the above compounds. SHE |